Numis Securities reaffirmed their buy rating on shares of Allergy Therapeutics (LON:AGY) in a research report sent to investors on Tuesday. Numis Securities currently has a GBX 45 ($0.61) price target on the stock.

A number of other brokerages have also recently commented on AGY. FinnCap reiterated a buy rating and issued a GBX 47 ($0.63) target price on shares of Allergy Therapeutics in a research report on Friday, October 20th. Panmure Gordon reissued a buy rating on shares of Allergy Therapeutics in a report on Thursday, September 28th.

Allergy Therapeutics (LON:AGY) opened at GBX 28.01 ($0.38) on Tuesday. Allergy Therapeutics has a 52-week low of GBX 19.50 ($0.26) and a 52-week high of GBX 39.50 ($0.53).

In other news, insider Tunde Otulana purchased 25,000 shares of the business’s stock in a transaction on Wednesday, October 11th. The shares were acquired at an average price of GBX 51 ($0.69) per share, with a total value of £12,750 ($17,160.16).

COPYRIGHT VIOLATION WARNING: “Allergy Therapeutics’ (AGY) “Buy” Rating Reiterated at Numis Securities” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The legal version of this piece can be viewed at

About Allergy Therapeutics

Allergy Therapeutics Plc is a pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum-free products. The Company’s segments are Central Europe, which includes segments, such as Germany, Australia, Switzerland and the Netherlands; Southern Europe, which includes Italy and Spain; the United Kingdom, and Rest of World.

Receive News & Stock Ratings for Allergy Therapeutics plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics plc and related stocks with our FREE daily email newsletter.